Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADRB1 | P08588 | 6/20 | 0.82 |
| ▸ | ADRB3 | P13945 | 5/20 | 0.82 |
| ▸ | LMNA | P02545 | 2/20 | 0.82 |
| ▸ | ADRB2 | P07550 | 2/20 | 0.82 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.82 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.82 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.82 |
| ▸ | NR1I2 | O75469 | 1/20 | 0.82 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.82 |
| ▸ | MEN1 | O00255 | 2/20 | 0.74 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.74 |
| ▸ | MAPT | P10636 | 1/20 | 0.74 |
| ▸ | BLM | P54132 | 1/20 | 0.74 |
| ▸ | PCNA | P12004 | 1/20 | 0.46 |
| ▸ | GAA | P10253 | 1/20 | 0.43 |
| ▸ | ABCB1 | P08183 | 2/20 | 0.42 |
| ▸ | POLB | P06746 | 1/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Xamoterol SCHEMBL64461 | 0.90 | ADRB1 (1.00) | ADRB1ADRB3LMNAADRB2NFKB1 | |
| Xamoterol SCHEMBL11533496 | 0.90 | ADRB1 (1.00) | ADRB1ADRB3LMNAADRB2NFKB1 | |
| Xamoterol SCHEMBL30897538 | 0.90 | ADRB1 (1.00) | ADRB1ADRB3LMNAADRB2NFKB1 | |
| Xamoterol SCHEMBL3702016 | 0.89 | ADRB1 (0.98) | ADRB1ADRB3LMNAADRB2NFKB1 | |
| Xamoterol SCHEMBL3697718 | 0.89 | ADRB1 (0.98) | ADRB1ADRB3LMNAADRB2NFKB1 | |
| SCHEMBL17038563 | 0.89 | LMNA (0.66) | ADRB1ADRB3LMNAADRB2NFKB1 | |
| Xamoterol SCHEMBL10584728 | 0.85 | ADRB2 (1.00) | ADRB1ADRB3LMNAADRB2NFKB1 | |
| Xamoterol SCHEMBL122201 | 0.85 | ADRB2 (1.00) | ADRB1ADRB3LMNAADRB2NFKB1 | |
| Xamoterol SCHEMBL3695282 | 0.85 | ADRB2 (1.00) | ADRB1ADRB3LMNAADRB2NFKB1 | |
| Xamoterol SCHEMBL1651584 | 0.85 | ADRB2 (1.00) | ADRB1ADRB3LMNAADRB2NFKB1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9849134-B2 | Method of improving cognition and social behavior in humans having deficits therein due to neurodegenerative disorders and compounds and compositions therefor | THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY (US) | 2017-12-26 | — | — | US | disclosed |
| US-20160184315-A1 | METHOD OF IMPROVING COGNITION AND SOCIAL BEHAVIOR IN HUMANS HAVING DEFICITS THEREIN DUE TO NEURODEGENERATIVE DISORDERS AND COMPOUNDS AND COMPOSITIONS THEREFOR | THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY (US) | 2016-06-30 | — | — | US | disclosed |
| WO-2015126915-A2 | METHOD OF IMPROVING COGNITION AND SOCIAL BEHAVIOR IN HUMANS HAVING DEFICITS THEREIN DUE TO NEUROLOGICAL DISORDERS AND COMPOUNDS AND COMPOSITIONS THEREFOR | THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY (US) | 2015-08-27 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160184315-A1 | METHOD OF IMPROVING COGNITION AND SOCIAL BEHAVIOR IN HUMANS HAVING DEFICITS THEREIN DUE TO NEURODEGENERATIVE DISORDERS AND COMPOUNDS AND COMPOSITIONS THEREFOR | ADRA1B, ADRB1, ADRA1A | ADRB1 2/4885ADRB3 9/4885LMNA 1438/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.